STOCK REPORT · 326030 · KOSPI
SK biopharmaceuticals Co., Ltd.
Overall grade
69 pointsMiddle bandOverall 69 points · Grade B, 1 points to Grade A
Financial summary
SK biopharmaceuticals Co., Ltd. (326030) has an overall grade of B from financial statements, with a score of 69 out of 100. Category scores are Earnings 99 (Grade S), Financial health 77 (Grade A) and Dividends 10 (Grade D). Data as of Oct 15, 2026.
Reported figures: ROE 30.65%, Operating margin 28.86%, Revenue growth +29.06%, Debt ratio 45.03%, Current ratio 231.45%, Dividend streak 0 yrs. Valuation: PER 22.02x, PBR 6.75x, Market cap ₩5.4T.
6 of the 9 graded metrics have values in this update.
This summary restates reported financial figures. It does not forecast share prices or returns.
Valuation
52-week range
Now at 1% of rangeWithin their own 52-week ranges, 6% of major Korean stocks sit lower than this one.
About these metrics
- PER
- Price to earnings ratio (market cap ÷ annual net profit). A lower value means a lower price relative to profit.
- PBR
- Price to book ratio (market cap ÷ net assets). Below 1x, the market value is below book value.
- Market cap
- Share price × shares outstanding. The value the market puts on the whole company.
- 52-week high
- The highest share price over the past year.
- 52-week low
- The lowest share price over the past year.
Scores by category
Each metric out of 100 · category score is the average of threeEarnings · Profitability
40% of overall · Top bandEach metric is scored out of 100, and the 99 above is the average of the three scores.
Metrics with values3 of 3
Fiscal year 2025 results
About these metrics
- ROE
- Return on equity. How much profit the company made on its own capital (equity).
- Operating margin
- Operating profit as a share of revenue. It shows the profitability of the core business.
- Revenue growth
- How much revenue changed compared with a year earlier.
Financial health
35% of overall · Upper bandEach metric is scored out of 100, and the 77 above is the average of the three scores.
Metrics with values2 of 3
Metrics shown as - in the table are not measured in this update, because the data has no such item.
About these metrics
- Debt ratio
- Liabilities as a share of equity. A lower ratio means the company relies less on debt.
- Current ratio
- Assets that can turn into cash within a year, as a share of debts due within a year. At 100% or more they cover those debts.
- Interest coverage
- How many times operating profit covers interest expense. Below 1x, operating profit does not cover interest.
Dividends
25% of overall · Bottom bandEach metric is scored out of 100, and the 10 above is the average of the three scores.
Metrics with values1 of 3
Metrics shown as - in the table are not measured in this update, because the data has no such item.
About these metrics
- Dividend yield
- Dividends paid over a year as a share of the current share price.
- Payout ratio
- The share of profit paid out as dividends. A very high ratio can be hard to keep up.
- Dividend streak
- How many years in a row the company has paid a dividend.
Metric scores are shown rounded to one decimal place, so a category score can differ by up to 1 point from a plain average of the three shown.
Strengths · Weaknesses
Strengths
- High profit relative to equity (ROE 30.65%)Above the median 13.5% of 37 Healthcare stocks
- High profitability in the core business (operating margin 28.86%)Above the median 24.2% of 40 Healthcare stocks
- Revenue is growing fast (+29.06% year on year)
- Low debt burden (debt ratio 45.03%)Below the median 54.9% of 36 Healthcare stocks
- Ample short-term liquidity (current ratio 231.45%)
Weaknesses
No notable weaknesses among metrics with values
A summary of only the metrics that stand out as notably good or weak against general benchmarks. Where a comparison is possible, the position against the median of stocks in the same sector is shown too. The stock count on each sector line covers only stocks with that metric, so it differs by metric.
Metrics that moved the overall score
- ROE+6.7 pts
- Revenue growth+6.5 pts
- Operating margin+6.5 pts
- Current ratio+5.0 pts
- Debt ratio+4.7 pts
- Interest coverage0.0 pts
- Payout ratio-3.1 pts
- Dividend yield-3.3 pts
- Dividend streak-3.3 pts
Metric scores run up to 100, and the middle score is 50. If all nine metrics scored 50, the overall score would also be 50. Each bar is the contribution of one metric: how far its score sits from the 50 baseline, converted by that metric weight. Right means it raised the overall score, left means it lowered it.
Adding the nine contributions above to the baseline gives 69.7 points, and this stock's overall score is 69. The overall score is calculated from unrounded metric scores and then truncated, while the contributions here are rounded to one decimal place, so the two can differ by up to 1 point. Metrics that are not measured values still carry a contribution, because their scores did go into the overall score and hiding them would hide part of the basis of the grade.
| Metric | SK biopharmaceuticals Co., Ltd. | Sector median | Rank in sector |
|---|---|---|---|
| PER | 22.0x | 29.0x | |
| PBR | 6.8x | 4.7x | |
| ROE | 30.6% | 13.5% | |
| Operating margin | 28.9% | 24.2% | |
| Debt ratio | 45.0% | 54.9% | |
| Dividend yield | - | 0.7% |
Grey values on the right are sector medians
Metric ranks in sector
Closer to 1st sits further left- PERRank 10 of 33, top 30%
- PBRRank 23 of 37, top 62%
- ROERank 6 of 37, top 16%
- Operating marginRank 16 of 40, top 40%
- Debt ratioRank 11 of 36, top 31%
On the rank strip, the left end is 1st. PER, PBR and debt ratio are ranked from the lowest value, and ROE, operating margin and dividend yield from the highest.
Healthcare stocks close in market cap rank
Sector medians cover the 40 Healthcare stocks listed on Jupick. Typical levels differ by sector, so this is reference information for a simple comparison and not a basis for investment decisions.
About these metrics
- PER
- Price to earnings ratio (market cap ÷ annual net profit). A lower value means a lower price relative to profit.
- PBR
- Price to book ratio (market cap ÷ net assets). Below 1x, the market value is below book value.
- ROE
- Return on equity. How much profit the company made on its own capital (equity).
- Operating margin
- Operating profit as a share of revenue. It shows the profitability of the core business.
- Debt ratio
- Liabilities as a share of equity. A lower ratio means the company relies less on debt.
- Dividend yield
- Dividends paid over a year as a share of the current share price.
Where this score sits
65.7% of the major stocks graded by Jupick score lower than this. Stocks in the same Grade B: 192.
- S112.8%
- A10927.3%
- BThis stock19248.1%
- C7117.8%
- D164%
The Grade B band runs from 50 to 69 points, 20 points wide. This stock's 69 points sit 19 points above the lower boundary, and 1 points remain to 70, where Grade A starts.
Within the Healthcare sector alone, it ranks No. 15 of 40 stocks with an overall score, and the median overall score of the sector is 65.
Unlike metric values, the overall score uses the same baseline for every market and currency, so Korean and US stocks share one sample. The grade boundaries of 85, 70, 50 and 30 points apply equally to every stock, so the counts above are how the sample actually splits at those boundaries. Because one point can decide a grade, two stocks with different grades can be closer in score than two stocks with the same grade. The shares and ranks here describe only the major stocks Jupick covers, not every listed stock.
Schedule
Earnings release
A date announced by the company.
The day the company publishes quarterly or annual results. Only the release date is covered, not the results. Release times are not covered, so only the date (Korea time) is shown. After the release, metrics such as revenue growth are updated at the next data refresh. For information only. Not investment advice.
Stocks with similar score profiles
| Stock | Earnings | Financial health | Dividends |
|---|---|---|---|
| SK biopharmaceuticals Co., Ltd. (326030, this stock) | 99 | 77 | 10 |
| BSAMSUNG BIOLOGICS CO.,LTD. | 99 | 71 | 10 |
| APalantir Technologies Inc. | 100 | 83 | 10 |
| AMonster Beverage Corporation | 96 | 83 | 10 |
| BNetflix, Inc. | 93 | 72 | 10 |
SK biopharmaceuticals Co., Ltd. (326030) has category scores of Earnings 99 · Financial health 77 · Dividends 10. These are the four major stocks graded in all three categories whose profiles come closest, and no category differs by more than 6 points.
The three scores are given by Jupick from public financial metrics, each out of 100. A similar profile means similar grading results only. It does not mean the share prices move alike.
Metrics to read together
Read one at a time, metrics split into strengths and weaknesses, but side by side two of them can be two sides of the same fact.
- ROEDebt ratio
ROE achieved without leaning on debt
ROE is high at 30.65% while the debt ratio is light at 45.03%. ROE tends to run high at companies with a lot of debt, because it grows as equity gets thinner, but this figure did not come that way.
This explains how reported figures relate to each other. It says nothing about future results or share prices. Metrics without measured values are left out.
Ratios as amounts
Base ₩10,000Every ratio metric of this stock, restated on the same amount. If each line used a different base, the amounts could not be compared, so every line starts from ₩10,000.
For every ₩10,000 of revenue: operating profit ₩2,890.Operating margin 28.9%
- For every ₩10,000 of equityyearly net profit ₩3,060
- If last year's revenue was ₩10,000this year's revenue ₩12,910
- For every ₩10,000 of equitydebt owed ₩4,500
- For every ₩10,000 of debt due within a yearassets turning into cash within a year ₩23,140
- For ₩10,000 of net profitmarket value ₩220,000
- For ₩10,000 of book equitymarket value ₩68,000
The ₩10,000 base is an assumption chosen for easy reading, not this company's actual revenue or equity. The values multiply the ratios shown as they are and round to the nearest won, so they can differ from the source by a few won. Metrics that make no sense as amounts are left out: values that are not measured, values that cannot be confirmed as measured, and loss-making cases where the base amount does not hold.
Metrics that decide the grade
Overall 69 · Grade BThe overall score recalculated with just one of the nine metrics set to the middle score of 50. Only one metric changes at a time, and the other eight stay as they are.
3 of the nine metrics would each take the overall score out of Grade B if only that metric were 50.
Overall score with only this metric at 50
- Dividend yieldAgrade72.3 pts
- Dividend streakAgrade72.3 pts
- Payout ratioAgrade72.1 pts
The scores above add up this stock's metric scores again with one of them set to 50. They are not new grades, and this stock's grade stays at B. Metric scores and contributions are rounded to one decimal place, so a change within 1 point of a boundary is not reported as a grade change. Changing two or more metrics at once was not calculated.
Where the share price enters the grade
The grade above turns 9 metrics into scores and combines them. Counting how many of them use the share price shows whether the grade moves when the price moves.
The 9 graded metrics stay the same when the share price moves.
- Earnings grade metrics (3)Does not use the share price0 of 3 metrics use the share price
- Financial health grade metrics (3)Does not use the share price0 of 3 metrics use the share price
- Dividend grade metrics (3)Does not use the share price0 of 3 metrics use the share price
- PER and PBRCome from the share price but are not scoredNot graded
For Korean stocks, Dividend yield is taken as stated in the disclosure, so it is not recalculated when the share price changes. What changes the grade is the next financial filing, not the share price.
Stocks with a value for each metric
The grade above uses 9 metrics. Each line shows how many major stocks have a value for that metric, so you can tell whether a blank is specific to this stock or common to most stocks.
6 of the 9 graded metrics have values.
- ROEHas a value378 of 399 stocks have a value
- Operating marginHas a value371 of 399 stocks have a value
- Revenue growthHas a value375 of 399 stocks have a value
- Debt ratioHas a value370 of 399 stocks have a value
- Current ratioHas a value360 of 399 stocks have a value
- Interest coverageNot reported190 of 399 stocks have a valueMore than half of stocks have no value
- Dividend yieldNot reported352 of 399 stocks have a valueMost stocks have a value
- Payout ratioNot reported348 of 399 stocks have a valueMost stocks have a value
- Dividend streakHas a value398 of 399 stocks have a value
Blank metrics on this stock: 3. Most other stocks have values for 2 of them, so those wait for this stock's filing.
Position in the market distribution
Korean stocksWhere the value of SK biopharmaceuticals Co., Ltd. sits when the Korean stocks on Jupick are lined up from the smallest value, ignoring sector. Left is smaller, right is larger, and the shaded part is the middle half.
The thin lower axis counts the position again within the same sector (Healthcare) only. 3 of the metrics with a lower axis sit in a different band from the whole market. On those lines, the bracket under the upper axis marks the middle half that the sector's stocks take on the market axis, and the short line inside is their middle.
- PER22.0xOn the upper axis, the middle half of these 9 stocks sits between 50.9% and 70.1%, with the middle at 62.3%, so on the market axis the sector itself is in the upper middle.
- PBR6.8xOn the upper axis, the middle half of these 16 stocks sits between 64.3% and 92.5%, with the middle at 78.1%.
- ROE30.6%
- Operating margin28.9%On the upper axis, the middle half of these 16 stocks sits between 3.2% and 93%, with the middle at 32.6%.
- Debt ratio45.0%
SK biopharmaceuticals Co., Ltd. metrics with no position on this page. Jupick does cover them, but they could not be lined up this time. The reason is given next to each.
- Dividend yield Could not be lined up this time
Won and dollar stocks have different metric levels, so they are counted in separate samples. This is only where a value sits in a line-up, not a sign of good or bad and not an investment judgement. Stocks without the metric, and loss-making stocks where PER or PBR does not hold, are left out of the sample. The remaining sample size is shown on each line. The sector axis is not drawn when the same-currency, same-sector sample has fewer than 8 stocks.
Korean and US yardsticks
Healthcare sectorWhere one value of SK biopharmaceuticals Co., Ltd. sits among Korean stocks in the same sector, and among US stocks. Only ratio metrics that compare across currencies are used.
3 of the 5 compared metrics sit in different bands on the two yardsticks.
- Debt ratio 45.0% Korean 16 stocks · lower middle · 43.8% have a smaller value US 20 stocks · lowest quarter · 15% have a smaller value Gap between yardsticks 28.8 pp
- PBR 6.8x Korean 16 stocks · lower middle · 43.8% have a smaller value US 21 stocks · upper middle · 71.4% have a smaller value Gap between yardsticks 27.6 pp
- PER 22.0x Korean 9 stocks · lowest quarter · 22.2% have a smaller value US 24 stocks · lower middle · 29.2% have a smaller value Gap between yardsticks 7 pp
Only metrics with at least 8 stocks on both sides are compared.
Investment notice
For information only. Not investment advice. Grades and figures are reference material calculated from public information. They do not ask anyone to trade a security and make no promise of returns. You are solely responsible for your investment decisions and their results, and Jupick accepts no legal liability for them.